Morphine
Duramorph, Embeda, Infumorph, Ms Contin (morphine) is a small molecule pharmaceutical. Morphine was first approved as Duramorph pf on 1984-09-18. It is used to treat dyspnea and intractable pain in the USA. The pharmaceutical is active against mu-type opioid receptor. In addition, it is known to target delta-type opioid receptor and kappa-type opioid receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Duramorph, Infumorph, Ms contin (generic drugs available since 1988-05-11, discontinued: Arymo, Astramorph, Avinza, Depodur, Kadian, Morphabond, Oramorph)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Morphine sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| MORPHINE SULFATE | Fresenius Kabi | N-204223 RX | 2013-10-30 | 5 products, RLD, RS |
| INFUMORPH | Hikma Pharmaceuticals | N-018565 RX | 1991-07-19 | 2 products, RLD, RS |
| DURAMORPH PF | Hikma Pharmaceuticals | N-018565 RX | 1984-09-18 | 2 products, RLD, RS |
| MORPHINE SULFATE | Hikma Pharmaceuticals | N-022195 RX | 2008-03-17 | 3 products, RLD |
| MORPHINE SULFATE | Hikma Pharmaceuticals | N-022207 RX | 2008-03-17 | 2 products, RLD, RS |
| MORPHINE SULFATE | Hospira | N-202515 RX | 2011-11-14 | 5 products, RLD |
| MS CONTIN | Purdue Pharma | N-019516 RX | 1987-05-29 | 5 products, RLD |
Show 12 discontinued
Morphine sulfate
+
Naltrexone hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| EMBEDA | Alpharma | N-022321 DISCN | 2009-08-13 | 6 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| avinza | New Drug Application | 2011-09-22 |
| duramorph | New Drug Application | 2020-01-28 |
| embeda | New Drug Application | 2010-01-22 |
| infumorph 200 infumorph 500 | New Drug Application | 2020-01-28 |
| kadian | New Drug Application | 2021-03-04 |
| mitigo | ANDA | 2021-04-20 |
| morphine sulfate | ANDA | 2023-06-12 |
| ms contin | New Drug Application | 2021-03-12 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| dyspnea | HP_0002094 | D004417 | R06.0 |
| intractable pain | — | D010148 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MORPHINE SULFATE, MORPHINE SULFATE, HIKMA | |||
| 2024-06-02 | NPP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Morphine Sulfate, Morphine Sulfate, Fresenius Kabi Usa | |||
| 9072781 | 2034-03-12 | DP | |
| 9192608 | 2034-03-12 | U-43, U-55 | |
| 9248229 | 2034-03-12 | DP | |
| Morphine Sulfate, Arymo Er, Zyla | |||
| 9044402 | 2033-07-01 | DP | U-1556 |
| 9549899 | 2033-07-01 | DP | U-1556 |
| Morphine Sulfate / Naltrexone Hydrochloride, Embeda, Alpharma Pharms | |||
| 8623418 | 2029-11-07 | U-1640 | |
| 7815934 | 2027-12-12 | DP | |
| 7682633 | 2027-06-19 | U-1510 | |
| 7682634 | 2027-06-19 | DP | |
| 8158156 | 2027-06-19 | U-1510 | |
| 8846104 | 2027-06-19 | DP | |
| 8877247 | 2027-06-19 | DP | |
| 8685443 | 2025-07-03 | U-1508 | |
| 8685444 | 2025-07-03 | DP | |
| Morphine Sulfate, Morphabond Er, Daiichi Sankyo Inc | |||
| 7955619 | 2028-08-12 | DP | |
| 10314788 | 2028-08-12 | DP | |
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07D: Antipropulsives
— A07DA: Antipropulsives
— A07DA52: Morphine, combinations
N: Nervous system drugs
— N02: Analgesics
— N02A: Opioid analgesics
— N02AA: Natural opium alkaloid analgesics
— N02AA01: Morphine
— N02AA51: Morphine, combinations
— N02AG: Opioids in combination with antispasmodics
— N02AG01: Morphine and antispasmodics
R: Respiratory system drugs
— R05: Cough and cold preparations
— R05D: Cough suppressants, excl. combinations with expectorants
— R05DA: Opium alkaloids and derivatives, cough suppressants
— R05DA05: Opium alkaloids with morphine
Clinical
Clinical Trials
874 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | G89.18 | 3 | 20 | 31 | 62 | 53 | 160 | |
| Pain | D010146 | EFO_0003843 | R52 | 6 | 25 | 29 | 33 | 27 | 112 |
| Analgesia | D000698 | 1 | 2 | 2 | 8 | 29 | 42 | ||
| Acute pain | D059787 | R52 | 5 | 10 | 9 | 12 | 9 | 41 | |
| Neoplasms | D009369 | C80 | 4 | 9 | 12 | 2 | 5 | 31 | |
| Chronic pain | D059350 | HP_0012532 | 3 | 6 | 3 | 11 | 4 | 25 | |
| Anesthesia | D000758 | 2 | 1 | 2 | 3 | 12 | 19 | ||
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 8 | 7 | 3 | 2 | — | 18 |
| Healthy volunteers/patients | — | 13 | 3 | — | 2 | 1 | 17 | ||
| Replacement arthroplasty knee | D019645 | — | — | 1 | 7 | 8 | 16 |
Show 139 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 1 | — | 5 | 6 |
| Lymphoma | D008223 | C85.9 | — | — | 2 | — | 1 | 3 | |
| Emergencies | D004630 | — | — | 3 | — | — | 3 | ||
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | 1 | — | 1 | — | 1 | 3 |
| Wounds and injuries | D014947 | T14.8 | — | — | 2 | — | 1 | 3 | |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | 1 | — | 1 | 2 | |
| Shoulder pain | D020069 | HP_0030834 | M25.51 | — | — | 1 | — | 1 | 2 |
| Leukemia | D007938 | C95 | — | — | 1 | — | 1 | 2 | |
| Myelodysplastic syndromes | D009190 | D46 | — | — | 1 | — | 1 | 2 | |
| Myeloproliferative disorders | D009196 | D47.1 | — | — | 1 | — | 1 | 2 |
Show 21 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 1 | — | — | 3 | 4 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | — | — | 2 | 3 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | 1 | 1 | — | — | 1 | 2 | |
| Diverticulitis | D004238 | EFO_1001460 | K57 | 1 | 1 | — | — | 1 | 2 |
| Treatment-resistant depressive disorder | D061218 | — | 1 | — | — | 1 | 2 | ||
| Heroin dependence | D006556 | EFO_0004240 | 1 | 1 | — | — | — | 1 | |
| Referred pain | D053591 | — | 1 | — | — | — | 1 | ||
| Rotator cuff injuries | D000070636 | M75.1 | — | 1 | — | — | — | 1 | |
| Infratentorial neoplasms | D015192 | C71.7 | — | 1 | — | — | — | 1 | |
| Rheumatic diseases | D012216 | M79.0 | 1 | 1 | — | — | — | 1 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | — | — | — | 2 | 3 |
| Physiological stress | D013312 | 1 | — | — | — | — | 1 | ||
| Vasoplegia | D056987 | 1 | — | — | — | — | 1 | ||
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
| Heart arrest | D006323 | EFO_0009492 | I46 | 1 | — | — | — | — | 1 |
| Gastric emptying | D005746 | 1 | — | — | — | — | 1 | ||
| Fatty liver | D005234 | 1 | — | — | — | — | 1 | ||
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | 1 | — | — | — | — | 1 |
| Traumatic brain injuries | D000070642 | S06 | 1 | — | — | — | — | 1 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatectomy | D006498 | — | — | — | — | 5 | 5 | ||
| Postoperative complications | D011183 | — | — | — | — | 3 | 3 | ||
| Inflammation | D007249 | — | — | — | — | 2 | 2 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | — | 2 | 2 |
| Conduction anesthesia | D000765 | — | — | — | — | 2 | 2 | ||
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | — | 2 | 2 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 2 | 2 |
| Urinary retention | D016055 | HP_0000016 | R33 | — | — | — | — | 1 | 1 |
| Thoracotomy | D013908 | — | — | — | — | 1 | 1 | ||
| Spine osteoarthritis | D055013 | EFO_1000787 | — | — | — | — | 1 | 1 |
Show 66 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MORPHINE |
| INN | — |
| Description | Morphine is a morphinane alkaloid that is a highly potent opiate analgesic psychoactive drug. Morphine acts directly on the central nervous system (CNS) to relieve pain but has a high potential for addiction, with tolerance and both physical and psychological dependence developing rapidly. Morphine is the most abundant opiate found in Papaver somniferum (the opium poppy). It has a role as an opioid analgesic, a mu-opioid receptor agonist, a plant metabolite, an environmental contaminant, a xenobiotic, a vasodilator agent, an anaesthetic, a drug allergen and a geroprotector. It is an organic heteropentacyclic compound, a tertiary amino compound and a morphinane alkaloid. It is a conjugate base of a morphine(1+). It derives from a hydride of a morphinan. |
| Classification | Small molecule |
| Drug class | opioid |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5 |
Target
Variants
Clinical Variant
No data
Financial
Arymo - Zyla Life Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 100,210 documents
View more details
Safety
Black-box Warning
Black-box warning for: Avinza, Duramorph, Embeda, Infumorph 200 infumorph 500, Kadian, Mitigo, Morphine sulfate, Ms contin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
138 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more